Targeting VEGF, EGFR, and other interacting pathways for gastric cancer-promises and reality

Annals of Surgical Oncology

Volumn 15, Issue 10, 2008, Pages 2981-2982

  Liakakos, T ^a   Fatourou, E ^a   Ziogas, D ^b   Lykoudis, E ^b   Roukos, Dimitrios H ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURGERY; GASTRECTOMY; GENE MUTATION; HIGH RISK POPULATION; LETTER; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; STOMACH CANCER; TUMOR GROWTH;

HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 51649108116     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-008-9870-9     Document Type: Letter

References (33)

1. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182 6
2. RK Jain DG Duda JW Clark 2006 Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nat Clin Pract Oncol 3 24 40
3. BP Schneider GW Sledge Jr 2007 Drug insight: VEGF as a therapeutic target for breast cancer Nat Clin Pract Oncol 4 181 9
4. K Miller M Wang J Gralow 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 76
5. D Cunningham YJ Chua 2007 East meets west in the treatment of gastric cancer N Engl J Med 357 1863 5
6. DH Roukos 2008 Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies Expert Rev Mol Diagn 8 29 39
7. Liakakos T, Roukos DH. More controversy than ever-challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 2008 Jan 23; [Epub ahead of print]. doi: 10.1245/s10434-007-9798-5
8. DH Roukos S Murray E Briasoulis 2007 Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer Cancer Biol Ther 6 308 12
9. DH Roukos 2008 HER2 and response to paclitaxel in node-positive breast cancer N Engl J Med 358 197
10. DH Roukos E Briasoulis 2007 Individualized preventive and therapeutic management of hereditary breast ovarian cancer Nat Clin Pract Oncol 4 578 90
11. E Lieto F Ferraraccio M Orditura 2008 Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients Ann Surg Oncol 15 69 79
12. DH Roukos AM Kappas 2005 Perspectives in the treatment of gastric cancer Nat Clin Pract Oncol 2 98 107
13. DH Roukos C Hottenrott A Encke 1994 Primary gastric lymphomas: a clinicopathologic study with literature review Surg Oncol 3 115 25
14. DH Roukos 2004 Early-stage gastric cancer: a highly treatable disease Ann Surg Oncol 11 127 9
15. DH Roukos AM Kappas 2002 Targeting the optimal extent of lymph node dissection for gastric cancer J Surg Oncol 81 59 62
16. AM Kappas M Fatouros DH Roukos 2004 Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 11 727 30
17. DH Roukos 1998 Extended lymphadenectomy in gastric cancer: when, for whom and why Ann R Coll Surg Engl 80 16 24
18. DH Roukos 2002 Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 9 220 1
19. E Briasoulis M Fatouros DH Roukos 2007 Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14 2691 5
20. E Briasoulis T Liakakos L Dova 2006 Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer Expert Rev Anticancer Ther 6 931 9
21. S Sakuramoto M Sasako T Yamaguchi 2007 Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810 2
22. D Cunningham WH Allum SP Stenning 2006 Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 11 20
23. JS Macdonald SR Smalley J Benedetti 2001 Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 725 30
24. JA Norton CM Ham J Van Dam 2007 CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer Ann Surg 245 873 9
25. DC Chung SS Yoon GY Lauwers 2007 Case records of the Massachusetts General Hospital. Case 22-2007. A woman with a family history of gastric and breast cancer N Engl J Med 357 283 91
26. Roukos DH. Linking contralateral breast cancer with genetics (editorial). Radiother Oncol 2008; 86:139-41
27. DH Roukos 2007 Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations N Engl J Med 357 1555 6
28. M Fatouros G Baltoyiannis DH Roukos 2008 The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations Ann Surg Oncol 15 21 33
29. DH Roukos AM Kappas E Tsianos 2002 Role of surgery in the prophylaxis of hereditary cancer syndromes Ann Surg Oncol 9 607 9
30. DH Roukos NJ Agnanti E Paraskevaidis 2002 Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations Ann Surg Oncol 9 941 3
31. NJ Agnantis E Paraskevaidis D Roukos 2004 Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance Ann Surg Oncol 11 1030 4
32. DH Roukos AM Kappas NJ Agnantis 2003 Perspectives and risks of breast-conservation therapy for breast cancer Ann Surg Oncol 10 718 21
33. M Fatouros DH Roukos I Arampatzis 2005 Factors increasing local recurrence in breast-conserving surgery Expert Rev Anticancer Ther 5 737 45